AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) – Research analysts at Jefferies Group reduced their Q1 2018 EPS estimates for AMAG Pharmaceuticals in a report issued on Monday, according to Zacks Investment Research. Jefferies Group analyst E. Yang now anticipates that the specialty pharmaceutical company will earn ($0.08) per share for the quarter, down from their prior estimate of $0.20. Jefferies Group currently has a “Hold” rating and a $20.00 target price on the stock. Jefferies Group also issued estimates for AMAG Pharmaceuticals’ Q2 2018 earnings at ($0.02) EPS, Q3 2018 earnings at ($0.57) EPS, Q4 2018 earnings at ($1.44) EPS, FY2018 earnings at ($2.11) EPS, FY2019 earnings at ($1.93) EPS, FY2020 earnings at ($1.61) EPS, FY2021 earnings at ($0.53) EPS and FY2022 earnings at $0.63 EPS.
Other research analysts have also recently issued reports about the company. Janney Montgomery Scott upgraded AMAG Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their price target for the stock from $16.65 to $45.00 in a research note on Thursday, February 15th. BidaskClub upgraded AMAG Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, March 2nd. Cantor Fitzgerald restated a “hold” rating and set a $17.00 price target on shares of AMAG Pharmaceuticals in a research note on Wednesday, February 14th. Piper Jaffray Companies restated a “hold” rating and set a $15.00 price target on shares of AMAG Pharmaceuticals in a research note on Thursday, January 18th. Finally, B. Riley restated a “hold” rating and set a $16.00 price target on shares of AMAG Pharmaceuticals in a research note on Tuesday, January 16th. Twelve analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $23.91.
AMAG Pharmaceuticals (AMAG) traded down $0.25 during trading hours on Wednesday, reaching $19.85. The company’s stock had a trading volume of 919,669 shares, compared to its average volume of 1,650,000. The company has a quick ratio of 1.60, a current ratio of 1.74 and a debt-to-equity ratio of 0.93. AMAG Pharmaceuticals has a one year low of $11.93 and a one year high of $24.85. The firm has a market capitalization of $676.67, a PE ratio of -3.21 and a beta of 0.28.
AMAG Pharmaceuticals (NASDAQ:AMAG) last released its quarterly earnings data on Tuesday, February 27th. The specialty pharmaceutical company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.68. AMAG Pharmaceuticals had a positive return on equity of 0.96% and a negative net margin of 32.66%. The firm had revenue of $158.30 million for the quarter, compared to analysts’ expectations of $158.84 million. During the same period in the prior year, the firm posted ($0.31) earnings per share. The firm’s quarterly revenue was up 4.4% on a year-over-year basis.
Several hedge funds and other institutional investors have recently made changes to their positions in AMAG. Bogle Investment Management L P DE acquired a new stake in shares of AMAG Pharmaceuticals in the fourth quarter valued at $4,352,000. Prudential Financial Inc. raised its stake in shares of AMAG Pharmaceuticals by 35.7% in the third quarter. Prudential Financial Inc. now owns 725,357 shares of the specialty pharmaceutical company’s stock valued at $13,382,000 after acquiring an additional 190,660 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of AMAG Pharmaceuticals by 18.5% in the second quarter. Dimensional Fund Advisors LP now owns 1,215,249 shares of the specialty pharmaceutical company’s stock valued at $22,361,000 after acquiring an additional 189,576 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of AMAG Pharmaceuticals by 25.1% in the fourth quarter. Renaissance Technologies LLC now owns 851,900 shares of the specialty pharmaceutical company’s stock valued at $11,288,000 after acquiring an additional 170,900 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. raised its stake in shares of AMAG Pharmaceuticals by 46.1% in the third quarter. Schwab Charles Investment Management Inc. now owns 424,875 shares of the specialty pharmaceutical company’s stock valued at $7,839,000 after acquiring an additional 134,080 shares in the last quarter.
TRADEMARK VIOLATION NOTICE: “Brokers Set Expectations for AMAG Pharmaceuticals, Inc.’s Q1 2018 Earnings (AMAG)” was originally published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at https://www.thelincolnianonline.com/2018/03/14/q1-2018-earnings-estimate-for-amag-pharmaceuticals-inc-amag-issued-by-jefferies-group.html.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.